Date on Master's Thesis/Doctoral Dissertation
Pharmacology and Toxicology
Pharmacology and Toxicology, MS
Metabolic dysfunction-associated steatotic liver disease (MASLD); Zinc supplementation; high fat diet; liver injury, therapeutic agent
Zinc deficiency is associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Previous studies show zinc supplementation improves steatosis, but its therapeutic effects in established MASLD remain unclear. We developed a model to characterize the effects of zinc supplementation on high-fat diet (HFD) induced MASLD and hypothesized established MASLD would be attenuated. Mice were fed control diet or HFD for 12 weeks and then grouped into normal or zinc-supplemented diets for 8 additional weeks. At euthanasia, plasma and liver tissues were collected for phenotypic analysis. Twelve weeks of HFD altered glucose clearance and body composition. Eight weeks of subsequent zinc supplementation did not change glucose handling, steatosis, or liver injury. Results from our model suggest 8-week zinc supplementation cannot reverse established MASLD. The HFD may have caused disease progression beyond rescue by the 8-week supplementation. Future studies will address these limitations, providing insights into zinc as a therapy for established MASLD.
Bolatimi, Oluwanifemi Esther, "Investigating the effects of subchronic dietary zinc supplementation on diet-induced metabolic dysfunction-associated steatotic liver disease." (2023). Electronic Theses and Dissertations. Paper 4199.
Retrieved from https://ir.library.louisville.edu/etd/4199